Altered metabolism and mitochondrial genome in prostate cancer

Journal of Clinical Pathology

Volumn 59, Issue 1, 2006, Pages 10-16

  Dakubo, G D ^a   Parr, R L ^a   Costello, L C ^b   Franklin, R B ^b   Thayer, R E ^a  

^a Genesis Genomics Inc   (Canada)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITATE HYDRATASE; CITRIC ACID; DNA; LIPID; MITOCHONDRIAL DNA; OXYGEN; PROTEIN; REACTIVE OXYGEN METABOLITE; ZINC;

CITRIC ACID CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRON TRANSPORT; ENERGY METABOLISM; ENZYME ACTIVITY; EPITHELIUM CELL; GENE MUTATION; HUMAN; HUMAN TISSUE; MITOCHONDRIAL GENETICS; MITOCHONDRIAL RESPIRATION; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

DNA, MITOCHONDRIAL; DNA, NEOPLASM; GENOME; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 30444437063     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.027664     Document Type: Review

References (49)

1. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
2. Warburg O. The metabolism of tumors. New York: Smith RR, 1931.
3. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer 2002;1:9.
4. Modica-Napolitano JS, Singh K. Mitochondria as targets for detection and treatment of cancer. Expert Rev Mol Med 2002;2002:1-19.
5. Augenlicht LH, Heerdt BG. Mitochondria: integrators in tumorigenesis? Nat Genet 2001;28:104-5.
6. Selak MA, Armour SM, Mackenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005;7:77-85.
7. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171:536-40.
8. De Marzo MA, Marchi VL, Epstein JI, et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-92.
9. Millar DS, Ow KK, Paul CL, et al. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 1999;18:1313-24.
10. Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. Bowen oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001;93:1872-9.
11. Gann PH, Ma J, Giovannucci E, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999;59:1225-30.
12. Esposito LA, Melov S, Panov A, et al. Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci USA 1999;96:4820-5.
13. Melov S, Coskun PE, Wallace DC. Mouse models of mitochondrial disease, oxidative stress, and senescence. Mutat Res 1999;434:233-42.
14. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-19.
15. Pozzan T, Rizzuto R. High tide of calcium in mitochondria. Nat Cell Biol 2000;2:E25-7.
16. Brenner C, Kroemer G. Apoptosis. Mitochondria-the death signal integrators. Science 2000;289:1150-1.
17. Morgan-Hughes JA, Sweeney MG, Cooper JM, et al. Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype. Biochim Biophys Acta 1995;1271:135-40.
18. Herrmann PC, Gillespie JW, Charboneau L, et al. Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics 2003;3:1801-10.
19. Jessie BC, Sun CQ, Irons HR, et al. Accumulation of mitochondrial DNA deletions in the malignant prostate of patients of different ages. Exp Gerontol 2001;37:169-74.
20. Jeronimo C, Nomoto S, Caballero OL, et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001;20:5195-8.
21. Chen JZ, Gokden N, Greene GF, et al. Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Res 2002;62:6470-4.
22. Chen JZ, Gokden N, Greene GF, et al. Simultaneous generation of multiple mitochondrial DNA mutations in human prostate tumors suggests mitochondrial hyper-mutagenesis. Carcinogenesis 2003;24:1481-7.
23. Mambo E, Gao X, Cohen Y, et al. Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci USA 2003;100:1838-43.
24. Alonso A. Setting up standards when interpreting mtDNA CR sequence data from tumors. JCP Online, eLetter, 15 Feb, 2005.
25. Tacha DE, Miller RT. Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue. Appl Immunohistochem Mol Morphol 2004;12:75-8.
26. Molinie V, Herve JM, Lebret T, et al. [Value of the antibody cocktail anti p63 + anti p504s for the diagnosis of prostatic cancer.] Ann Pathol 2004;24:6-16.
27. Bensasson D, Zhang D, Hartl DL, et al. Mitochondrial pseudogenes: evolution's misplaced witnesses. Trends Ecol Evol 2001;16:314-21.
28. Petros JA, Baumann AK, Ruiz-Pesini E, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A 2005;102:719-24.
29. Davies KJ. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life 1999;48:41-7.
30. van der Walt JM, Nicodemus KK, Martin ER, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 2003;72:804-11.
31. Khan MA, Partin AW, Mangold LA, et al. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 2003;62:866-71.
32. Haggman MJ, Macoska JA, Wojno KJ, et al. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 1997;158:12-22.
33. Sadar MD, Gleave ME. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res 2000;60:5825-31.
34. Ripple MO, Henry WF, Rago RP, et al. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997;89:40-8.
35. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
36. Costello LC, Franklin RB. The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000;59:269-82.
37. Costello LC, Feng P, Milon B, et al. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis 2004;7:111-17.
38. Sing KK. Mitochondria damage checkpoint in apoptosis and genome stability. FEMS Yeast Res 2004;5:127-32.
39. Rishi I, Baidouri H, Abbasi JA, et al. Prostate cancer in African American men is associated with down regulation of zinc transporters. Appl Immunohistochem Mol Morphol 2003;11:253-60.
40. Costello LC, Liu Y, Zou J, et al. Mitochondrial aconitase gene expression is regulated by testosterone and prolactin in prostate epithelial cells. Prostate 2000;42:196-202.
41. Costello LC, Liu Y, Franklin RB. Testosterone stimulates the biosynthesis of maconitase and citrate oxidation in prostate epithelial cells. Mol Cell Endocrinol 1995;112:45-51.
42. Lim SD, Sun C, Lambeth JD, et al. Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 2005;62:200-7.
43. Graziewicz MA, Day BJ, Copeland WC. The mitochondrial DNA polymerase as a target of oxidative damage. Nucleic Acids Res 2002;30:2817-24.
44. Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000;287:2017-19.
45. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998;20:291-3.
46. Hayes RB, Pottern LM, Strickler H, et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000;82:718-25.
47. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002;13:72-9.
48. Gao N, Ding M, Zheng JZ, et al. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem 2002;277:31963-71.
49. Amuthan G, Biswas G, Zhang SY, et al. Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J 2001;20:1910-20.